G. Terracina

发表

Identification of presenilin 1-selective γ-secretase inhibitors with reconstituted γ-secretase complexes.

J. Clader, D. Burnett, E. Parker, 2011, Biochemistry.

Detecting tau in serum of transgenic animal models after tau immunotherapy treatment

P. Davies, C. d’Abramo, G. Terracina, 2016, Neurobiology of Aging.

Characterization of the reconstituted gamma-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin [correction of nacastrin], aph-1a, and pen-2.

Jie Shen, E. Parker, Julie Lee, 2005, Biochemistry.

Solution-phase parallel synthesis of carbamates as gamma-secretase inhibitors.

J. Clader, Lixin Song, G. Terracina, 2008, Journal of combinatorial chemistry.

Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology

Lynn A. Hyde, J. Melchor, J. Hess, 2015, Molecular Neurodegeneration.

Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors.

T. Kowalski, Unmesh G. Shah, Julie Lee, 2010, Bioorganic & medicinal chemistry letters.

Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitors.

Lynn A. Hyde, W. Greenlee, Mark D. McBriar, 2013, Bioorganic & medicinal chemistry letters.

Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides.

E. Parker, L. Zhang, G. Terracina, 2001, Biochemistry.

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

N. Hastings, B. Butts, R. Hargreaves, 2017, Molecular Neurodegeneration.

Iminoheterocycles as gamma-secretase modulators.

Lynn A. Hyde, J. Voigt, Zhaoning Zhu, 2010, Bioorganic & medicinal chemistry letters.

Discovery of SCH 900229, a Potent Presenilin 1 Selective γ-Secretase Inhibitor for the Treatment of Alzheimer's Disease.

W. Greenlee, R. Xu, J. Clader, 2012, ACS medicinal chemistry letters.

Purification and Preliminary Characterization of a Serine Hydrolase Involved in the Microbial Degradation of Polychlorinated Biphenyls*

J. Bolin, S. Seah, L. Eltis, 1998, The Journal of Biological Chemistry.

Discovery of a Tetrahydrobenzisoxazole Series of γ-Secretase Modulators.

Lynn A. Hyde, W. Greenlee, A. Palani, 2017, ACS medicinal chemistry letters.

Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation.

William Greenlee, Lynn Hyde, Xia Chen, 2012, Journal of medicinal chemistry.

Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology

Lynn A. Hyde, J. Melchor, J. Hess, 2015, Molecular Neurodegeneration.

MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy

Lynn A. Hyde, E. Hostetler, J. Uslaner, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Cyclic hydroxyamidines as amide isosteres: discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo.

Lynn A. Hyde, W. Greenlee, Xiaohong Zhu, 2012, Journal of medicinal chemistry.

Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates.

Lynn A. Hyde, W. Greenlee, A. Stamford, 2016, Journal of medicinal chemistry.

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice

Lynn A. Hyde, N. Hastings, B. Butts, 2017, Molecular Neurodegeneration.

Discovery of a Novel, Potent Spirocyclic Series of γ-Secretase Inhibitors.

Lynn A. Hyde, R. Xu, J. Clader, 2015, Journal of medicinal chemistry.

The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors.

W. Greenlee, G. Terracina, Lili Zhang, 2009, Bioorganic & medicinal chemistry letters.